MedTrace Logo

129Xe MRI Cardiopulmonary

NCT06038630 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 125

Last updated 2026-02-04

No results posted yet for this study

Summary

The goal of this NIH-sponsored study is to characterize three biomarkers derived from 129Xe gas exchange MRI and to understand how they change in response to interventions.

Conditions

Interventions

DRUG

Hyperpolarized Xe129

Hyperpolarized xenon will be administered in multiple doses in volumes up to 25% of subject TLC followed by a breath hold of up to 15 seconds.

OTHER

Oxygen Administration

Oxygen administration

Sponsors & Collaborators

  • National Institutes of Health (NIH)

    collaborator NIH

  • Bastiaan Driehuys

    lead OTHER

Principal Investigators

  • Joseph Mammarappallil, MD · Duke University

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-01-12
Primary Completion
2028-06-30
Completion
2028-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06038630 on ClinicalTrials.gov